-
Investigating the Mechanism of Jiawei Weijin Decoction in Treating Non-Small Cell Lung Cancer Using Network Pharmacology, Bioinformatics Analysis and Experimental Validation
25 Sep 2025 08:23 GMT
… natural drugs to inhibit the target of SPP1 in treating the … on combination and versus drug therapies. Biomed Pharmacother. 2021;138:111350. … and reducing errors. Stat Med. 1996;15(4):361– … of osteopontin in cancer development and treatment. Heliyon. 2023;9(10 …
-
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
11 Sep 2025 11:30 GMT
… stage biopharmaceutical company developing small molecule precision … endpoints included pharmacokinetics, food effect, pharmacodynamic measures of … events and no treatment-related adverse events … the potential to treat both phenylketonuria (PKU) and chronic …
-
Vanguard, BlackRock, and Armistice Capital Maintain Large Stakes in PTC Therapeutics Amid Pipeline Developments
16 Sep 2025 23:15 GMT
… , when the FDA approved Sephience (sepiapterin) to treat phenylketonuria (PKU) across all disease … Palynziq have long dominated pharmacologic treatment for PKU. But Reuters reported … large positions amid these developments are consistent with index …
-
Maze Therapeutics Drug Shows Potential to Top Asset Acquired by Otsuka for $800M
14 Sep 2025 18:59 GMT
… treatment-related complications leading to discontinuation of the study drug … Maze aims to treat is phenylketonuria, in which … . BioMarin Pharmaceutical markets two FDA-approved medications for the … which is in development for treating patients with APOL1 …
-
Maze reports positive results from Phase I trial of PKU and CKD treatment
12 Sep 2025 17:19 GMT
Maze Therapeutics has shared positive outcomes from the randomised Phase I study of the oral SLC6A19 inhibitor, MZE782, for treating phenylketonuria (PKU) and chronic kidney disease (CKD).
The placebo-controlled, double-blind trial, which involved 112 …
-
Takeda poaches top Lilly exec; Maze soars on early PKU drug data
12 Sep 2025 15:24 GMT
… adverse events reported. Notably, treatment resulted in urine levels … in-class profile” in phenylketonuria as well as chronic … Willi syndrome drug Vykat was reported to the FDA’s … Ionis Pharmaceuticals over rival drugs the two companies have been developing …
-
Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential
11 Sep 2025 18:08 GMT
… therapy for patients with phenylketonuria (PKU), an inherited metabolic … kidney disease (CKD).
Pharmacokinetics (PK)
MZE782 demonstrated … Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive … events, and no treatment-related adverse events …
-
PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment
08 Sep 2025 18:13 GMT
On Saturday, BioMarin Pharmaceutical Inc. BMRN released … adolescents with phenylketonuria (PKU), a rare metabolic disorder.
The trial enrolled 55 … Read: BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 … facing a U.S. FDA decision by Nov. 30 …
-
BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism
06 Sep 2025 15:29 GMT
… the treatment of adolescents with phenylketonuria (PKU), … to treat adults with PKU. … to drug discovery and development, …
Katherine Powell
BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
(415) 455-7558 …
-
Alzheimer’s Therapy Is Coming to the Home With FDA Approval of Injectable Eisai, Biogen Drug
02 Sep 2025 13:18 GMT
… FDA in 2021 as a treatment for pediatric growth hormone deficiency.
—Apellis Pharmaceuticals drug … for treating the blood disorder paroxysmal nocturnal hemoglobinuria. A formulation developed as …
About
© 1995-2025